Karin Walker

Direktor/Vorstandsmitglied bei CYCLACEL PHARMACEUTICALS, INC.

Vermögen: 11 106 $ am 31.05.2024

60 Jahre

Health Technology

Process Industries

Finance

Aktive Positionen von Karin Walker

Unternehmen	Position	Beginn	Ende
PROTHENA CORPORATION PLC	Comptroller/Controller/Auditor	20.05.2013	-
CYCLACEL PHARMACEUTICALS, INC.	Direktor/Vorstandsmitglied	09.11.2020	-
CYCLACEL PHARMACEUTICALS, INC.	Independent Dir/Board Member	09.11.2020	-

Unternehmen	Position	Beginn	Ende
VINCERX PHARMA, INC.	Direktor/Vorstandsmitglied	05.03.2020	23.12.2020
VINCERX PHARMA, INC.	Independent Dir/Board Member	05.03.2020	23.12.2020
AFFYMAX, INC.	Comptroller/Controller/Auditor	02.10.2012	01.05.2013
AMYRIS, INC.	Comptroller/Controller/Auditor	01.01.2009	01.09.2012
CV Therapeutics, Inc. CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases	Comptroller/Controller/Auditor	01.06.2006	01.08.2009
Ernst & Young US LLP Ernst & Young US LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young US LLP was engaged in providing accounting services. The company was headquartered in Pittsburgh, PA.	Corporate Officer/Principal	-	-

California Polytechnic State University (San Luis Obispo)

Undergraduate Degree

International

Vereinigte Staaten	8
Irland	2

Operativ

Comptroller/Controller/Auditor	4
Director/Board Member	2
Independent Dir/Board Member	2

Sektoral

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	4
AFFYMAX, INC.	Health Technology
PROTHENA CORPORATION PLC	Health Technology
AMYRIS, INC.	Process Industries
CYCLACEL PHARMACEUTICALS, INC.	Health Technology

Private Unternehmen	3
CV Therapeutics, Inc. CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases	Health Technology
LifeSci Acquisition Corp. LifeSci Acquisition Corp. Financial ConglomeratesFinance LifeSci Acquisition Corp. operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The company was founded on December 19, 2018 and is headquartered in New York, NY.	Finance
Ernst & Young US LLP Ernst & Young US LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young US LLP was engaged in providing accounting services. The company was headquartered in Pittsburgh, PA.	Commercial Services